An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies.

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date13/01/22 → 31/12/27
View all
View less

Keywords

  • Malignant Haematology
  • Multiple myeloma
  • Clinical trial